| Autor: |
Noémie Lang, Aurélie Ayme, Chang Ming, Jean‑Damien Combes, Victor N. Chappuis, Alex Friedlaender, Aurélie Vuilleumier, José L. Sandoval, Valeria Viassolo, Pierre O. Chappuis, S. Intidhar Labidi-Galy |
| Jazyk: |
angličtina |
| Rok vydání: |
2023 |
| Předmět: |
|
| Zdroj: |
Swiss Medical Weekly, Vol 153, Iss 3 (2023) |
| Druh dokumentu: |
article |
| ISSN: |
1424-3997 |
| DOI: |
10.57187/smw.2023.40055 |
| Popis: |
BACKGROUND: Carriers of germline pathogenic variants of the BRCA1 gene (gBRCA1) tend to have a higher incidence of haematological toxicity upon exposure to chemotherapy. We hypothesised that the occurrence of agranulocytosis during the first cycle of (neo-)adjuvant chemotherapy (C1) in breast cancer (BC) patients could predict gBRCA1 pathogenic variants. PATIENTS AND METHODS: The study population included non-metastatic BC patients selected for genetic counselling at Hôpitaux Universitaires de Genève (Jan. 1998 to Dec. 2017) with available mid-cycle blood counts performed during C1. The BOADICEA and Manchester scoring system risk-prediction models were applied. The primary outcome was the predicted likelihood of harbouring gBRCA1 pathogenic variants among patients presenting agranulocytosis during C1. RESULTS: Three hundred seven BC patients were included: 32 (10.4%) gBRCA1, 27 (8.8%) gBRCA2, and 248 (81.1%) non-heterozygotes. Mean age at diagnosis was 40 years. Compared with non-heterozygotes, gBRCA1 heterozygotes more frequently had grade 3 BC (78.1%; p = 0.014), triple-negative subtype (68.8%; p |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
